IMPaCT Investigator Highlights
Tomasz Beer, M.D.; Elisabeth I. Heath, M.D.; Celestia S. Higano, M.D.; Howard I. Scher, M.D.
Oregon Health and Sciences University
Karmanos Cancer Institute Wayne State University
University of Washington Fred Hutchinson Cancer Research
Sidney Kimmel Center for Prostate and Urologic Cancers Memorial Sloan-Kettering
Prostate Cancer Clinical Trials Consortium: Bringing the "Best of the Best" to Prostate Cancer Patients
Robert K. Bright, Ph.D.
Texas Tech University
Prostate Cancer Vaccines Targeting Over-Expressed Self-Oncoantigens
Arul M. Chinnaiyan, M.D., Ph.D.
University of Michigan Medical School
Therapeutic Targeting of SPINK-1-Positive Prostate Cancer
Scott Dehm, Ph.D.
Masonic Cancer Center of the University of Minnesota
Androgen Receptor and Castration-Resistant Prostate Cancer
Phillip Febbo, M.D.
University of California, San Franscisco, Mt. Zion Medical Center
Increased P38 MAPK Is Responsible for Docetaxel Resistance in Prostate Cancer
Evan T. Keller, D.V.M., Ph.D.
University of Michigan
Novel Application of Aptamer Selection (Pheno-SELEX) to Target the Invasive Phenotype Successfully Creates Anti-Metastatic Aptamers
Isaac J. Powell, M.D., F.A.C.S.
Wayne State University and Karmanos Cancer Institute
The Influence of Metabolic Syndrome on Prostate Cancer Progression and Risk of Recurrence in African-American and European-American Men
Dr. Powell's Poster
R. Renee Reams, Ph.D.
College of Pharmacy & Pharmaceutical Sciences, Florida A&M University
Genomics of Prostate Cancer Health Disparity
Marianne Sadar, Ph.D.
British Columbia Cancer Agency
Regression of Castrate-Recurrent Prostate Cancer by Antagonists to the Androgen Receptor N-Terminal Domain
Vasan Yegnasubramanian, M.D., Ph.D.
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Integrative Analysis of Genetic and Epigenetic Alterations in Lethal Metastatic Prostate Cancer
Dr. Yegnasubramanian's Poster